Publication Name	World Journal of Cardiology
Manuscript ID	25170
Country	United States

Received	2016-02-26 08:42
Peer-Review Started	2016-02-26 14:16
To Make the First Decision	2016-04-15 08:52
Return for Revision	2016-04-15 11:02
Revised	2016-04-28 00:00
Second Decision	2016-05-16 08:43
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2016-06-02 15:53
Articles in Press	2016-06-02 15:53
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-07-06 18:12
Publish the Manuscript Online	2016-07-18 14:15

ISSN	1949-8462 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Allergy
Manuscript Type	Review
Article Title	Novel role of phosphodiesterase inhibitors in the management of end-stage heart failure
Manuscript Source	Invited Manuscript
All Author List	Abhishek Jaiswal, Vinh Q Nguyen, Thierry H Le Jemtel and Keith C Ferdinand
Funding Agency and Grant Number
Corresponding Author	Keith C Ferdinand, MD, Tulane School of Medicine, Tulane University Heart and Vascular Institute, 1430 Tulane Avenue, SL# 48, New Orleans, LA 70112, United States. kferdina@tulane.edu
Key Words	Milrinone; Advanced heart failure; Bridge to beta blocker; Combination therapy; Inotrope support
Core Tip	Heart failure (HF) patients requiring chronic inotropic support are considered hemodynamically labile and may escape the benefits of evidence based HF therapy (HFTx). Chronic milrinone infusion may be bene-ficial as a bridge to introduction of HFTx. We discuss evidence that intravenous milrinone support may allow introduction of beta blocker (BB). We propose that HF patients who are intolerant to BB therapy may benefit from intravenous milrinone as a bridge to BB initiation. When used together, BB mitigates cardiotoxic effects and decreases the risk of arrhythmias associated with milrinone. Whereas, milrinone does not attenuate the clinical benefits of BB therapy.
Publish Date	2016-07-18 14:15
Citation	Jaiswal A, Nguyen VQ, Le Jemtel TH, Ferdinand KC. Novel role of phosphodiesterase inhibitors in the management of end-stage heart failure. World J Cardiol 2016; 8(7): 401-412
URL	http://www.wjgnet.com/1949-8462/full/v8/i7/401.htm
DOI	http://dx.doi.org/10.4330/wjc.v8.i7.401

Full Article (PDF)	WJC-8-401.pdf
Full Article (Word)	WJC-8-401.doc
Manuscript File	25170-Review.doc
Answering Reviewers	25170-Answering reviewers.pdf
Audio Core Tip	25170-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	25170-Conflict-of-interest statement.pdf
Copyright License Agreement	25170-Copyright assignment.pdf
Video	Video_20160226023023.mpg
Video	25170-Video core tip.m4v
Peer-review Report	25170-Peer-review(s).pdf
Scientific Misconduct Check	25170-Scientific misconduct check.pdf
Scientific Editor Work List	25170-Scientific editor work list.pdf